Monograph
Statins vs PCSK9 Inhibitors vs Bempedoic Acid vs Inclisiran
Modern lipid management has four major pharmacological pillars: statins (the dominant first-line therapy), PCSK9 inhibitor monoclonal antibodies (evolocumab and alirocumab, the most potent LDL-lowering option), bempedoic acid (the newer non-statin…
By Kristopher Crawford
·
30 May 2026
·
5 min read
Modern lipid management has four major pharmacological pillars: statins (the dominant first-line therapy), PCSK9 inhibitor monoclonal antibodies (evolocumab and alirocumab, the most potent LDL-lowering option), bempedoic acid (the newer non-statin…
In the full monograph
- What it is, and how it works
- What the evidence shows — randomized trials, observational data, animal studies, graded and cited
- Dose, form, and timing
- What to expect, and how soon
- Who should be careful, and what to check first
- The verdict
MEMBERS
Read the full monograph
Members get every monograph in the library, the research assistant, and the stack tracker — with a 30-day money-back guarantee. Not ready? Start free with the Proven Supplements Starter Guide.